Differentiating Benign from Malignant Thyroid Tumors by Kinase Activity Profiling and Dabrafenib BRAF V600E Targeting

SIMPLE SUMMARY: Recurrent non-medullary thyroid cancer (NMTC) is difficult to treat and therapy options are limited. Of the available compounds, serine/threonine kinase (STK) inhibitors are currently widely used. However, this form of targeted therapy is not always effective and additional response-...

Descripción completa

Detalles Bibliográficos
Autores principales: Hilhorst, Riet, van den Berg, Adrienne, Boender, Piet, van Wezel, Tom, Kievits, Tim, de Wijn, Rik, Ruijtenbeek, Rob, Corver, Willem E., Morreau, Hans
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10527361/
https://www.ncbi.nlm.nih.gov/pubmed/37760447
http://dx.doi.org/10.3390/cancers15184477

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10527361/
https://www.ncbi.nlm.nih.gov/pubmed/37760447
http://dx.doi.org/10.3390/cancers15184477

Ejemplares similares